Identification of Notch pathway-related biomarkers in patients with idiopathic pulmonary fibrosis
Yang S., Bao Y., Zhao H., Zhang C., Wang Y., Li K.
Prospective Study, published in PLoS One (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- PLoS One (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41481554
- PMCID
- PMC12758733
- DOI
- 10.1371/journal.pone.0339287
Abstract (original English)
The involvement of Notch pathway-related genes (NPRGs) in idiopathic pulmonary fibrosis (IPF) remains inadequately understood. This study identified novel NPRG-associated biomarkers in IPF through integrated analysis of the GSE28042 dataset and NPRG gene sets, with the goal of uncovering potential therapeutic targets. Initially, 7 overlapping candidate genes were identified by intersecting 1,361 differentially expressed genes (DEGs) between IPF and control samples, 4,883 key module genes associated with IPF, and 428 known NPRGs. Four biomarkers-IL4, PLXND1, NBEA, and GATA2-were prioritized using machine learning methods. Immune infiltration analysis, conducted with the CIBERSORT algorithm (v2.0.4), revealed that IL4, NBEA, and GATA2 were significantly positively correlated with resting dendritic cells and negatively correlated with follicular helper T cells. Additionally, drug target prediction and pathway enrichment analyses suggested potential associations between these biomarkers and oxidative stress-related pathways. RT-qPCR validation using human blood samples confirmed significant down-regulation of IL4 and NBEA while PLXND1 was significantly up-regulated in patients with IPF compared to healthy controls. These biomarkers may contribute to the pro-fibrotic microenvironment, and their dysregulation is linked to the pathogenesis of pulmonary fibrosis. In summary, the identi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.